Defunct Company
Total Trials
8
As Lead Sponsor
3
As Collaborator
5
Total Enrollment
245
NCT00532259
CT-011 MAb in DLBCL Patients Following ASCT
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 31, 2007
Completion: Aug 31, 2011
NCT00962936
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Phase: Phase 1/2
Start: Sep 30, 2009
Completion: Jan 31, 2013
NCT00966251
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Start: Oct 31, 2009
Completion: Jun 30, 2011
NCT00904722
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Role: Collaborator
Start: Jan 31, 2010
Completion: Apr 30, 2015
NCT02077959
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase 1
Start: Mar 3, 2014
Completion: May 24, 2019
NCT04196413
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)
Start: Jun 4, 2020
Completion: Jul 31, 2043
NCT04573140
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Start: Dec 13, 2021
Completion: Jul 1, 2029
NCT05887882
Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
Start: May 31, 2024
Completion: Dec 31, 2027